Navigation Links
Watson Confirms OxyContin® Patent Challenge
Date:3/25/2011

armaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on For
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
(Date:1/22/2015)... Jan. 22, 2015 Increasing sophistication among enterprise buyers ... localization purchasing in 2015, says Moravia CMO, ... recent study by market research firm Common Sense Advisory, ... for their translation and localization needs. "From a language ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... continuance needed to reduce cardiovascular,risks, ROCHESTER, Minn., ... therapy for enlarged prostates experience significant,surges in blood ... heart attack or,stroke, according to new research findings ... Clinic-led study of 185 consecutive patients who received,transurethral ...
... designed to validate drug targets for the fatal,neurodegenerative ... April 8, 2008 The ALS,Therapy Development Institute ... agreement with the Allen Institute for Brain Science ... using diseased tissues from a,preclinical animal model of ...
Cached Medicine Technology:Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 2Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 3ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science 2ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science 3
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Carinsurancesavings.biz has released ... accidental death and dismemberment insurance . , Purchasing an ... can be very advantageous. This type of rider provides benefits ... dismemberment can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... two sets of brothers with autism, Johns Hopkins scientists ... to be linked very specifically to the severity of ... interacting protein 1), is a blueprint for a traffic-directing ... brain cells across which chemical signals flow. ...
... A study led by researchers at the University of Michigan ... drug compounds they developed shrank tumors, with few side effects. ... cancer, looked at two compounds designed to activate a protein ... a significant number of human cancers. In some cases, it ...
... Machinery (ACM) has named Takeo Kanade, the U.A. and ... at Carnegie Mellon University, the 2010 winner of the ... computer vision and robotics. , The Newell Award, named ... School of Computer Science, recognizes career contributions that have ...
... cancer is the second most common cancer among women, with ... estrogen over a long period of time is one factor ... One way a woman can combat this risk factor ... with the activity of estrogen. Now, researchers at Fox ...
... Reporter , TUESDAY, April 5 (HealthDay News) -- In ... study, researchers report that risks to postmenopausal women who ... ended the treatment. The study found that ... and blood clots, which were elevated while they were ...
... April 6 (HealthDay News) -- Poor overall health seems ... survivors, according to the results of a new study. ... breast cancer survivors participating in the After Breast Cancer ... shortly after diagnosis, and follow-up occurred an average of ...
Cached Medicine News:Health News:Gene linked to severity of autism's social dysfunction 2Health News:Gene linked to severity of autism's social dysfunction 3Health News:CMU's Takeo Kanade wins ACM/AAAI Award for career contributions to computer vision, robotics 2Health News:Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 3Health News:Overall Health May Be Key to Beating Breast Cancer 2
... Operation: , Standby: All toggle switches at off ... pulse/s); 10 s (1 pulses/10 s) , Tetanus: ... pulses/s) , Train-Of-Four: Single (4 pulses/2 s); repeat ... Output Current: Adjustable from 0-70 mA(HI range) 0-6.0mA ...
... of Operation: , Double Burst : 2 60-ms bursts ... 1 s (1 pulse/s) , Tetanus: 50 Hz ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: Adjustable ... Monophasic pulses (200-us duration) , Indicators: Battery LED (green) ...
... Modes of Operation: , Standby: A standby ... stimulus pulses. , Twitch: 1 s (1 pulse/s) ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: ... Square Wave Monophasic pulses (200-us duration) , Indicators: ...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
Medicine Products: